PO.BCS02.05 · 生物信息与计算
Genie-ADLA: A deep learning algorithm for methylation-based multiple cancer early detection (MCED)
作者与单位
摘要 Abstract
Background: Methylation-based analysis of cell-free DNA (cfDNA) has emerged as a key technology for MCED. However, existing approaches rely on traditional machine learning algorithms, which inherently limit detection performance. With the rapid advancement of artificial intelligence (AI), we have developed Genie-ADLA, a deep learning algorithm designed specifically for MCED. By integrating state-of-the-art deep neural network architectures with the intrinsic patterns inherent in methylation data, Genie-ADLA significantly enhanced MCED performance.
Methods: Genie-ADLA was trained and evaluated on a dataset of 4,781 participants aged 40-75 years, including 2,702 pathologically confirmed cancer cases across 16 cancer types and 2,079 non-cancer controls (NCT06217900). The training set comprised 3,217 samples (1,756 cancer cases and 1,461 non-cancer controls), and the model's performance was evaluated on an independent test set of 1,564 samples (618 non-cancer controls and 946 cancer cases). To address challenges inherent to methylation data-high dimensionality, sparsity, and noise-we applied feature dimensionality reduction and embedding strategies, reducing computational burden, mitigating overfitting, and improving learning efficiency. An ensemble learning approach further strengthened robustness and generalization.
Results: Across all stages of 16 cancer types, Genie-ADLA achieved an overall sensitivity of 63.43% (600/946, 95% CI: [60.26%, 66.50%]) at 99.3% (612/618, 95% CI: [97.90%, 99.64%]) specificity in the test cohort. Compared with the XGBoost model trained on the same dataset, Genie-ADLA demonstrated improved overall sensitivity in 11 of the 16 cancer types, with an average increase of 4.86%.For stage I-III cancer patients, the sensitivities at 99.3% specificity showed notable gains over XGBoost: colorectal cancer achieved 76.98% (97/126, 95% CI: [68.65%, 84.01%]), an improvement of 9.52% from 67.46%; esophageal cancer reached 80.95% (51/63, 95% CI: [69.09%, 89.75%]), up 6.35% from 74.60%; breast cancer reached 37.14% (26/70, 95% CI: [25.89%, 49.52%]), improving by 5.71% from 31.43%. Lung cancer was subdivided into adenocarcinoma and non-adenocarcinoma, with stage I-III sensitivities of 40.90% (27/66, 95% CI: [28.95%, 53.71%]) in adenocarcinoma, an increase of 10.6%, and 84.44% (38/45, 95% CI: [70.54%, 93.51%]) in non-adenocarcinoma, improving by 2.22%.
Conclusions: Genie-ADLA, leveraging advanced deep neural network architectures and data processing strategies, substantially elevates the performance ceiling of methylation-based early cancer detection, offering a new paradigm for AI-driven cancer screening.
利益披露 Disclosure
K. Chen, None..
Z. Li, None..
X. Wu, None..
J. Huang, None..
G. Lv, None..
W. Wen, None..
D. Zhang, None..
X. Zhao, None..
D. Wang, None..
Z. Liu, None..
L. Sun, None..
S. Wang, None..
X. Li, None..
Z. Li, None..
J. Tai, None..
J. Yang, None..
Z. Wei, None..
M. Cai, None..
Q. Zhang, None..
S. He, None..
S. Yi, None..
S. Qu, None..
W. Zhao, None..
X. Yu, None..
R. Guo, None..
J. Lian, None..
D. Yang, None..
H. Lu, None..
X. Guo, None..
Y. Zhang, None..
Z. Liu, None..
Y. Ye, None..
C. Lin, None..
J. Gao, None..
X. Liu, None..
Y. Guo, None..
S. Ding, None.
G. Zhao,
Shanghai Xiaohe Medical Laboratory Co. Ltd. Employment.
Y. Yang,
Shanghai Xiaohe Medical Laboratory Co. Ltd. Employment.
J. Li,
Shanghai Xiaohe Medical Laboratory Co. Ltd. Employment.
S. Chen,
Shanghai Xiaohe Medical Laboratory Co. Ltd. Employment.
H. Yu,
Shanghai Xiaohe Medical Laboratory Co. Ltd. Employment.
F. Liu,
Shanghai Xiaohe Medical Laboratory Co. Ltd. Employment.
Y. Wang,
Shanghai Xiaohe Medical Laboratory Co. Ltd. Employment.
M. Li,
Shanghai Xiaohe Medical Laboratory Co. Ltd. Employment.
B. Zhu,
Shanghai Xiaohe Medical Laboratory Co. Ltd. Employment.
Y. Li,
Shanghai Xiaohe Medical Laboratory Co. Ltd. Employment.
X. Wu,
Shanghai Xiaohe Medical Laboratory Co. Ltd. Employment.
F. Yang, None..
J. Wang, None.